HORSHAM, Pa.--(BUSINESS WIRE)--Galleon Pharmaceuticals announced today a clinically significant outcome in a clinical proof-of-concept study evaluating the ability of its lead investigational drug, GAL-021, to successfully regulate respiratory drive, a key requirement to prevent respiratory complications in high-risk surgical patients. This is the first time a drug has been shown to regulate and protect respiratory drive from drug-induced respiratory depression. In this study, intravenous GAL-021 was able to reverse respiratory depression under challenging conditions including high doses of opioids and elevated carbon-dioxide levels, which can be particularly problematic for post-surgical and sleep apnea patients. The Company is actively seeking funding to advance this promising candidate into a broad Phase II program.
